Frazier Life Sciences Acquisition Corp II (FLSC)
NASDAQ: FLSC · Real-Time Price · USD
10.27
-0.03 (-0.29%)
Oct 22, 2026, 4:00 PM EDT - Market closed
Company Description
Frazier Life Sciences Acquisition Corp II focuses on effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses.
The company was incorporated in 2026 and is based in Palo Alto, California.
Frazier Life Sciences Acquisition Corp II
| Country | United States |
| Founded | 2026 |
| IPO Date | Oct 14, 2026 |
| Industry | Shell Companies |
| Sector | Financials |
| CEO | Albert Cha |
Contact Details
Address: 1001 Page Mill Road, Building 4, Suite 200B Palo Alto, California 94304 United States | |
| Phone | 650 325 5156 |
Stock Details
| Ticker Symbol | FLSC |
| Exchange | NASDAQ |
| Share Class | Class A Shares |
| Reporting Currency | USD |
| IPO Price | $10.00 |
| CIK Code | 2153598 |
| ISIN Number | KYG371031017 |
| Employer ID | 98-1964369 |
| SIC Code | 6770 |
Key Executives
| Name | Position |
|---|---|
| Albert Cha, M.D., Ph.D. | Chief Executive Officer and Director |
| Fran Adams | Chief Financial Officer |
| Kevin Li, M.D. | Chief Business Officer |
| Ali Jackson, J.D. | General Counsel |
| William C. Fairey, Jr. | Director |
| Benjamin L. Palleiko | Director, Chairman |
| R. Scott Struthers, Ph.D. | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 22, 2026 | SCHEDULE 13G | Filing |
| Oct 22, 2026 | 8-K | Current Report |
| Oct 21, 2026 | SCHEDULE 13D | Filing |
| Oct 21, 2026 | SCHEDULE 13G | Filing |
| Oct 21, 2026 | SCHEDULE 13G | Filing |
| Oct 16, 2026 | SCHEDULE 13G | Filing |
| Oct 15, 2026 | 8-K | Current Report |
| Oct 14, 2026 | 424B4 | Prospectus |
| Oct 13, 2026 | EFFECT | Notice of Effectiveness |
| Oct 13, 2026 | CERT | Certification by an exchange approving securities for listing |